2023 World Conference on Lung Cancer (Posters)-EP12.03. Adverse Events and Outcomes in Patients with Oncogenic Driver Mutation-positive NSCLC Receiving Targeted Therapy Following Immunotherapy

EP12.03. Adverse Events and Outcomes in Patients with Oncogenic Driver Mutation-positive NSCLC Receiving Targeted Therapy Following Immunotherapy - PDF(Slides)

Back to course

Pdf Summary

This study investigated the outcomes and adverse events in patients with non-small cell lung cancer (NSCLC) who received tyrosine kinase inhibitors (TKI) after immunotherapy. The study used real-world data from the Glans-Look Lung Cancer Research program database in Alberta, Canada. It found that 30% of patients experienced additional serious adverse events (SAE) while receiving TKI, with 67% of them requiring treatment termination. The most common SAE was increased hepatic enzymes. Pneumonitis and pericarditis occurred in 3.8% of patients, with a median time to SAE presentation of 40 days. The study also found that 36.8% of patients experienced a treatment break as a management decision for SAE. Patients over the age of 70 were more likely to experience over 70 SAE. The study did not find any associations between SAE status and overall survival, progression-free survival, or Eastern Cooperative Oncology Group performance scale at TKI initiation. The findings suggest that completing molecular profiling before treatment decisions can help balance treatment efficacy and safety. Additionally, expanding testing in early-stage disease may identify patients with oncogenic driver mutations who can benefit from TKI therapy while minimizing potential toxicity. More real-world data are needed to determine the best approach to exploit oncogene driver mutations in NSCLC treatment. The study provides insights into the safety outcomes of prescribing targeted therapy following immunotherapy in NSCLC patients with oncogenic driver mutations.

Asset Subtitle

Michelle Dean

Meta Tag

Speaker Michelle Dean

Topic Metastatic NSCLC: Targeted Therapy - Other

Keywords

non-small cell lung cancer

NSCLC

tyrosine kinase inhibitors

immunotherapy

adverse events

hepatic enzymes

pneumonitis

pericarditis

molecular profiling

oncogenic driver mutations